搜索结果

   MAN2A1

靶点ID:TCMBANKGE010490

靶点别名:AMan II; GOLIM7; MANA2; MANII

靶点描述:mannosidase alpha class 2A member 1

染色体:5

染色体位置:5q21.3

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:6824

OMIM_Link:154582

Ensembl_Link:ENSG00000112893

   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族
   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN004839 GCS AIDS000694; 14257-69-3; 6490-70-6 (.ALPHA.-FORM); C08349; KBioGR_000970; Spectrum5_000756; (2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)tetrahydropyran-2,4,5-triol; BSPBio_002086; beta-D-Glucosamine; KBio2_001311; IDI1_000261; (2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol; KBio3_001306; CHEBI:28393; SPBio_000477; 90-77-7; NINDS_000261; (2R,3R,4R,5S,6R)-3-amino-6-methylol-tetrahydropyran-2,4,5-triol; KBio2_003879; Spectrum2_000519; D-Glucose, 2-deoxy-2-Amino-; KBio1_000261; AIDS-000694; KBio2_006447; Spectrum3_000443; Spectrum4_000565; Spectrum_000831; KBioSS_001311; 28905-10-4 (.BETA-FORM); DivK1c_000261 C6H13NO5 179.17 C(C1C(C(C(C(O1)O)N)O)O)O
TCMBANKIN012700 coumestrol NCIMech_000078; CCRIS 7311; A-Lactone; API0002121; Tox21_200032; MolPort-003-846-031; US8552057, 3; HMS3374A07; 3,9-Dihydroxy-6H-benzofuro[3,2-c]-[1]benzopyran-6-one; 6H-Benzofuro[3,2-c][1]benzopyran-6-one,3,9-dihydroxy-; Cumostrol; CHEBI:3908; C-16836; VZ31590; LS-35394; S00280; 3,9-dihydroxy-[1]benzofuro[3,2-c]chromen-6-one; MFCD00016885; SMP2_000163; DSSTox_RID_76572; 27885_FLUKA; 6H-Benzofuro[3, 3,9-dihydroxy-; 5-19-06-00405 (Beilstein Handbook Reference); BRN 0266702; 479-13-0; NSC22842; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone; C10205; 3,9-dihydroxy-[1]benzoxolo[3,2-c]chromen-6-one; AC1NQYXV; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, delta-lactone (6CI); NCGC00018124-01; DSSTox_CID_2399; CTK8F8799; Coumestrol, >=95.0% (HPLC); NCI60_001863; 4CN-2508; ZZIALNLLNHEQPJ-UHFFFAOYSA-N; BIDD:ER0114; NCGC00018124-03; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one #; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-; A1-00298; NSC 22842; 3,9-Dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one; CCG-35536; NCGC00018124-06; 3,9-bis(oxidanyl)-[1]benzofuro[3,2-c]chromen-6-one; ZINC1219; NCGC00257586-01; 3,9-Dihydroxy-benzo[4,5]furo[3,2-c]chromen-6-one; AIDS011954; SCHEMBL22012; UNII-V7NW98OB34; 3-Benzofurancarboxylic acid, 2-(2,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone; 6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-; MLS000069446; CCG-36200; LMPK12090018; 3-Benzofurancarboxylic acid,4-dihydroxyphenyl)-6-hydroxy-, .delta.-lactone; 7,12-Dihydroxycoumestan; CS-6343; D02DML; CHEMBL30707; 3,9-dihydroxy-6-benzofurano[3,2-c]chromenone; ZINC00001219; 5,14-dihydroxy-8,17-dioxatetracyclo[8.7.0.0^{2,7}.0^{11,16}]heptadeca-1(10),2,4,6,11(16),12,14-heptaen-9-one; Oprea1_222511; MLS000738006; EINECS 207-525-6; 3,9-Dihydroxycoumestan; Coumestrol, BioReagent, suitable for fluorescence, >=97.5% (HPLC); A827386; DTXSID6022399; CAS-479-13-0; FT-0603177; ST50320052; 2-(2,4-Dihydroxyphenyl)-6-hydroxy-3-benzofurancarboxylic Acid ; 3,9-dihydroxybenzofurano[3,2-c]chromen-6-one; 3,9-dihydroxybenzo[d]chromeno[4,3-b]furan-6-one; NCGC00023462-03; AIDS-011954; V0359; Cumoestrol; DSSTox_GSID_22399; Cumoesterol; NCGC00018124-05; Coumestrol; NCGC00018124-04; V7NW98OB34; ZB000278; 3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one; ST5320052; AN-6463; Cumestrol; NCGC00023462-04; NCGC00018124-02; CC-25990; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihdyroxy-; NSC-22842; 3,9-dihydroxybenzofuro[3,2-c]chromen-6-one; AKOS028111776; HMS2235B05; Coumesterol; COUMESTROL; BDBM23451; SMR000059001; HY-N2335; 27883_FLUKA C15H8O5 268.22 C1=CC2=C(C=C1O)OC3=C2C(=O)OC4=C3C=CC(=C4)O
TCMBANKIN020714 RAM ALPHA-RHAMNOSE; 6-deoxy-alpha-L-mannopyranose; alpha-L-rhamnopyranose; (2R,3R,4R,5R,6S)-6-methyltetrahydropyran-2,3,4,5-tetrol; alpha-L-Rha; CHEBI:27907; alpha-L-Mannomethylose; alpha-6-Deoxy-L-mannose; ZINC03861280; CHEBI:27848; alpha-L-Rhamnose; C02476; RAA; alpha-L-rhamnosides; alpha-L-Rhamnoside; 6-deoxy-alpha-L-mannopyranoside; (2R,3R,4R,5R,6S)-6-methyloxane-2,3,4,5-tetrol; 10030-85-0 C6H14O6 182.17 g/mol CC(C(C(C(C=O)O)O)O)O.O
TCMBANKIN027150 BDF Fructose, pyranose form; (2R,3S,4R,5R)-2-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol; CHEBI:41005; Frutabs; 7660-25-5; (2R,3S,4R,5R)-2-(hydroxymethyl)oxane-2,3,4,5-tetrol; ZINC03861095; Fructopyranose, beta-D-; beta-D-Fructopyranose; HSDB 526; BRN 1423189; 4-01-00-04402 (Beilstein Handbook Reference); (2R,3S,4R,5R)-2-methyloltetrahydropyran-2,3,4,5-tetrol C6H12O6 180.16 C1C(C(C(C(O1)(CO)O)O)O)O
TCMBANKIN031363 dimethyl sulfoxide C2H6OS 78.14 g/mol CS(=O)C
TCMBANKIN038143 stachyose O-alpha-D-galactopyranosyl-(1->6)o-alpha-D-galactopyranosyl-(1->6)O-alpha-D-galactopyranosyl-beta-D-fructofuranoside; 10094-58-3; C01613; Stachyose; beta-D-fructofuranosyl alpha-D-galactopyranosyl-(1->6)-alpha-D-galactopyranosyl-(1->6)-alpha-D-glucopyranoside; 470-55-3; alpha-D-Galp-(1->6)-alpha-D-Galp-(1->6)-alpha-D-Glcp-(1<->2)-beta-D-Fruf; (2R,3R,4S,5S,6R)-2-[[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)-2-tetrahydrofuranyl]oxy]-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]oxymethyl]-2-tetrahydropyranyl]oxymethyl]tet; (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxymethyl]oxane-3,4,5-triol; (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)tetrahydrofuran-2-yl]oxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxymethyl]tetra; (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-dimethylol-tetrahydrofuran-2-yl]oxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylol-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-3,; CHEBI:17164 C24H42O21 667 O([H])[C@]1([H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@@]([H])(OC([H])([H])[C@]2([H])[C@]([H])(O[H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@@]([H])(O[C@]3([H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]([H])(C([H])([H] )O[H])O[C@]3([H])O[C@]4([C@@]([H])(O[H])[C@]([H])(O[H])[C@@]([H])(C([H])([H])O[H])O4)C([H])([H])O[H])O2)O[C@]1([H])C([H])([H])O[H]
TCMBANKIN044652 alpha-D-fructofuranose CHEBI:37720; (2S,3S,4S,5R)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol; (2S,3S,4S,5R)-2,5-dimethyloltetrahydrofuran-2,3,4-triol; (2S,3S,4S,5R)-2,5-bis(hydroxymethyl)tetrahydrofuran-2,3,4-triol C6H12O6 180.156 O([H])C([H])([H])[C@](O[H])(O[C@]([H])(C([H])([H])O[H])[C@@]1([H])O[H])[C@@]1([H])O[H]
TCMBANKIN058470 NOJ 19130-96-2; AIDS-000139; Bio1_001393; BSPBio_000993; 1-DEOXYNOJIRIMYCIN; DNM; Bio1_000415; NCGC00025085-02; 3,4,5-Piperidinetriol, 2-(hydroxymethyl)-, (2R-(2alpha,3beta,4alpha,5beta))-; Bio1_000904; 1-Deoxymannojirimycin; 1,5-Dideoxy-1,5-imino-D-glucitol; (2R,3R,4R,5S)-2-Hydroxymethyl-piperidine-3,4,5-triol; (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol; AIDS000139; SMP2_000333; 70956-02-4; 1,5-Deoxy-1,5-imino-D-mannitol; 73285-50-4 (HCL); (2R,3R,4R,5S)-2-methylolpiperidine-3,4,5-triol; 1-DEOXY-NOJIRIMYCIN; DNJ; 3gbe; 2jke; 3gxt; 2pwd; 1- deoxynojirimycin; 1-deoxynojirimycin; 3qfz; 4iid; 1-deoxynojirimycin; 1-deoxynojirimicin C6H13NO4 163.17 g/mol C1C(C(C(C(N1)CO)O)O)O
TCMBANKIN058472 ASO 1,5-ANHYDROSORBITOL; (2R,3S,4R,5S)-2-(hydroxymethyl)tetrahydropyran-3,4,5-triol; 154-58-5; 1,5-Anhydroglucitol; C07326; CHEBI:16070; Polygalytol; 1,5-Anhydro-D-glucitol; (2R,3S,4R,5S)-2-(hydroxymethyl)oxane-3,4,5-triol; 1,5-Anhydro-D-sorbitol; (2R,3S,4R,5S)-2-methyloltetrahydropyran-3,4,5-triol; EINECS 205-829-3; D-Glucitol, 1,5-anhydro- C6H12O5 164.16 C1C(C(C(C(O1)CO)O)O)O
   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000023 Skin and Connective Tissue Diseases; Immune System Diseases Abnormality of the immune system Disease or Syndrome disease
TCMBANKDI003248 Nutritional and Metabolic Diseases; Endocrine System Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI004030 Hemic and Lymphatic Diseases Abnormality of blood and blood-forming tissues Disease or Syndrome disease
TCMBANKDI009216 Behavior and Behavior Mechanisms - Mental Process phenotype
TCMBANKDI011883 - - Mental Process phenotype
TCMBANKDI012074 Neoplasms; Female Urogenital Diseases and Pregnancy Complications Abnormality of prenatal development or birth; Abnormality of the genitourinary system; Neoplasm Neoplastic Process disease
TCMBANKDI015485 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction disease

Home | Browse | Search | Predict | Data | Contact | Help

Copyright © KUST | 滇IICP备16009434号-1 | Dai SX Lab